NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) — Financial Flexibility Index
NewAmsterdam Pharma Company N.V. Ordinary Shares (NAMS) has a Financial Flexibility Index of -0.56x as of September 2025. Free cash flow of $-32.73 Million (operating CF $-32.77 Million minus capex $42.00K) represents -1% of total liabilities ($58.36 Million). Also explore NewAmsterdam Pharma Company N.V. Ordinar annual equity growth to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
NewAmsterdam Pharma Company N.V. Ordinary Shares Financial Flexibility Index (2020–2024)
Historical Financial Flexibility Index trend for NewAmsterdam Pharma Company N.V. Ordinary Shares across 5 annual periods. Check NewAmsterdam Pharma Company N.V. Ordinar (NAMS) strategic investment index to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for NewAmsterdam Pharma Company N.V. Ordinary Shares (2020–2024)
Year-by-year free cash flow to debt coverage for NewAmsterdam Pharma Company N.V. Ordinary Shares. For the full company profile including market capitalisation, see NewAmsterdam Pharma Company N.V. Ordinar (NAMS) market capitalisation.
| Year | Flexibility Index | Free Cash Flow (USD) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | -1.47x | $-157.89 Million | $-158.56 Million | $107.12 Million | ▲ +38.7% |
| 2023 | -2.41x | $-141.19 Million | $-141.22 Million | $58.70 Million | ▼ -1170.0% |
| 2022 | 0.22x | $10.89 Million | $10.66 Million | $48.43 Million | ▲ +108.7% |
| 2021 | -2.60x | $-29.49 Million | $-29.51 Million | $11.36 Million | ▼ -339.5% |
| 2020 | -0.59x | $-7.33 Million | $-7.34 Million | $12.41 Million | — |